Tag: immunotherapy
-
Reporting from the American Society of Clinical Oncology
Our Research Communications & Engagement Officer, Arshiya, shares some of the most exciting results from the American Society of Clinical Oncology (ASCO) conference
-
Nivolumab fails to meet its target
Nivolumab, an immunotherapy drug, has been unsuccessful in improving overall survival in a phase 3 clinical trial when tested in newly diagnosed glioblastoma with unmethylated MGMT
-
Researchers discover a new target for immunotherapy
Researchers design immune cells to target a protein found on two thirds of glioblastomas, the most common and lethal primary brain tumour
-
New phase 2 clinical trial testing immunotherapy drug announced
A phase 2 clinical trial testing an immunotherapy drug called ipilimumab to treat patients with glioblastomas has been announced in the United Kingdom
-
Immunotherapy drug shows lack of promise in Phase 3 clinical trial for glioblastoma patients
Last week Bristol-Myers Squibb announced the initial results from their Phase 3 clinical trial that was assessing the effectiveness and safety of the immunotherapy drug Nivolumab in patients with recurrent glioblastoma.
-
Immunotherapy and gene therapy double attack against glioblastoma shows therapeutic potential
A combinatorial approach using immunotherapy and gene therapy has been explored by researchers at the University of Michigan against the highly aggressive brain tumour, glioblastoma (GBM).
-
New Zealand tech firm produce virtual reality cancer immunotherapy visualisation
New Zealand-based technology company, Genulin Interactive, have produced a cutting-edge visualisation of cancer immunotherapy.